U.S. markets closed
  • S&P 500

    4,224.79
    +58.34 (+1.40%)
     
  • Dow 30

    33,876.97
    +586.89 (+1.76%)
     
  • Nasdaq

    14,141.48
    +111.10 (+0.79%)
     
  • Russell 2000

    2,286.09
    +48.35 (+2.16%)
     
  • Crude Oil

    73.58
    +1.94 (+2.71%)
     
  • Gold

    1,783.70
    +14.70 (+0.83%)
     
  • Silver

    26.01
    +0.05 (+0.18%)
     
  • EUR/USD

    1.1922
    +0.0057 (+0.48%)
     
  • 10-Yr Bond

    1.4840
    +0.0340 (+2.34%)
     
  • GBP/USD

    1.3935
    +0.0126 (+0.91%)
     
  • USD/JPY

    110.3000
    +0.1500 (+0.14%)
     
  • BTC-USD

    32,398.85
    -3,422.09 (-9.55%)
     
  • CMC Crypto 200

    785.83
    -64.52 (-7.59%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,010.93
    -953.15 (-3.29%)
     

Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Fusion's lead candidate, FPI-1434, in combination with Merck's Keytruda in patients with solid tumors expressing insulin-like growth factor 1 receptor (IGF-1R).

  • The planned Phase 1/2 combination trial will evaluate the safety, tolerability, and pharmacokinetics of FPI-1434 in combination with pembrolizumab.

  • The study is expected to initiate approximately six to nine months after achieving the recommended Phase 2 dose in the ongoing Phase 1 study of FPI-1434 monotherapy.

  • Under the terms of the agreement, Fusion will sponsor the study, and Merck will supply Keytruda.

  • FPI-1434 is a radioimmunoconjugate designed to target and deliver alpha emitting medical isotopes to cancer cells expressing IGF-1R, a receptor that is overexpressed on many tumor types.

  • Price Action: FUSN shares are up 2.16% at $8.98 on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.